Last reviewed · How we verify

NCT02855775: PK-MAB

Monoclonal Antibodies Elimination in Breast Cancer Patient

Completed NA Last updated 19 April 2021
What this trial tests

NA trial testing additional blood sample in Breast Cancer in 76 participants. Completed in 15 October 2020.

Timeline
25 September 2013
Primary endpoint
15 October 2020
15 October 2020

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Besancon
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment76
Start date25 September 2013
Primary completion15 October 2020
Estimated completion15 October 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Besancon

Who can join

Adults 18 to 80, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Study evaluates covariables being able to potentially influence the elimination of the monoclonal antibodies (trastuzumab, bevacizumab and denosumab).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of additional blood sample

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Besancon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02855775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing